---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-007305"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:27:10.205708+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# TOI Q4 revenue $71M (+36.6% YoY), net loss narrows; beats revised 2022 guidance

## Summary
- Q4 2022 revenue $71M (+36.6% YoY); gross profit $16M (+87.6% YoY); net loss $9.5M vs $10.2M prior year.
- Adjusted EBITDA loss improved to $(4.6)M from $(5.6)M in Q4 2021.
- Ended FY2022 with $132M cash; completed $110M Deerfield investment in Aug 2022.
- Surpassed top end of revised 2022 guidance for revenue, gross profit, and adjusted EBITDA.
- Market count expanded to 15 from 10; capitated membership added 100k+ lives.

## SEC filing metadata
- accession: 0001628280-23-007305
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000162828023007305/0001628280-23-007305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000162828023007305/toi-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-007305
- JSON: https://secwatch.observer/filing/0001628280-23-007305.json
- Plain text: https://secwatch.observer/filing/0001628280-23-007305.txt

## Key facts
- Earnings Releases
  Oncology Institute, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $71 million, net income $9.5 million, EPS $(0.11) and $(0.15).
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $71 million
  - Net income: $9.5 million
  - EPS: $(0.11) and $(0.15)
  - Result: reported results
  source text: • Consolidated revenue of $71 million, an increase of 36.6% from $52 million compared to the prior year quarter • Gross profit of $16 million, an increase of 87.6% compared to the prior year quarter • Net loss of $9.5 million compared to net loss of $10.2 million for the prior year quarter • Basic and diluted earnings per share of $(0.11) and $(0.15), respectively, compared to $(0.13) for the prior year quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000162828023007305/0001628280-23-007305-index.htm
- Earnings Releases
  Oncology Institute, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000162828023007305/0001628280-23-007305-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.